Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7105691 | 0.99 | ADRB2 (0.60) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| SCHEMBL6915308 | 0.89 | ADRB2 (0.47) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| SCHEMBL6912195 | 0.88 | ADRB2 (0.47) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL7113371 | 0.88 | ADRB2 (0.46) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| SCHEMBL6908028 | 0.88 | ADRB3 (0.56) | ADRB3ADRA1A | |
| Hydrochloric Acid SCHEMBL7110210 | 0.88 | ADRB2 (0.46) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| SCHEMBL6908024 | 0.88 | ADRB3 (0.56) | ADRB3ADRA1A | |
| SCHEMBL6911772 | 0.88 | ADRB3 (0.56) | ADRB3ADRA1A | |
| Hydrochloric Acid SCHEMBL7106644 | 0.87 | ADRB3 (0.55) | ADRB3ADRA1A | |
| Hydrochloric Acid SCHEMBL7108639 | 0.87 | ADRB3 (0.55) | ADRB3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882707-B1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 2003-10-08 | — | — | EP | claimed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | claimed |
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | KADOWAKI TAKASHI (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-0882707-B1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| US-20030073644-A1 | Combinations comprising a beta-agonist and a further antidiabetic agent | SMITHKLINE BEECHAM P.L.C. | 2003-04-17 | — | — | US | disclosed |
| US-6545053-B1 | Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-04-08 | — | — | US | disclosed |
| US-6187809-B1 | BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ADRB3, MC2R, NR3C1 | ADRB2 14/4885ADRB1 5/4885ADRB3 1/4885 |
| US-20030073644-A1 | Combinations comprising a beta-agonist and a further antidiabetic agent | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885ADRB1 1/4885ADRB3 3/4885 |
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | ADIPOR1, FABP4, ADIPOR2 | ADRB2 17/4885ADRB1 11/4885ADRB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.